Categories
Artificial intelligence

Elix chief exec aims to lead Japan’s AI drug discovery field

Elix chief exec aims to lead Japan's AI drug discovery field

In the USA and in Europe, interest in the potential for artificial intelligence to transform different aspects of the life sciences industry is at an all-time high.

Much of the attention has been paid to the potential for an algorithmic, machine learning-based approach to drug discovery.

The charge has been led by companies such as French firm Iktos, Britain’s Exscientia (Nasdaq: EXAI) and BenevolentAI, and American firms including Seismic Therapeutic,…

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyzes and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.

.

Leave a Reply

Your email address will not be published.